Family Medicine
RCT | Helicobacter pylori eradication may prevent peptic ulcer bleeding in older patients prescribed aspirin in primary care.
11 Nov, 2022 | 14:00h | UTCNews Release: Cutting the risk of stomach bleeding, occasionally caused by regular aspirin use – University of Nottingham
Commentary on Twitter
New @TheLancet – the HEAT trial of H pylori eradication for primary prevention of peptic ulcer bleeding in older patients prescribed aspirin in primary care (1/4)https://t.co/9SlP3y6DGf #gitwitter #medtwitter
— Rob Brierley (@Rob__Brierley) November 4, 2022
RCT | Dual endothelin antagonist Aprocitentan is effective for resistant hypertension.
11 Nov, 2022 | 13:59h | UTCDual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Commentaries:
Endothelin Receptor Antagonist Effective in Resistant Hypertension: PRECISION – TCTMD
Phase 2RCT | Baxdrostat reduces BP in patients with treatment-resistant hypertension.
11 Nov, 2022 | 13:57h | UTCPhase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension – New England Journal of Medicine (link to abstract – $ for full-text)
Commentaries:
Big Drops in Blood Pressure With Baxdrostat: BrigHTN Phase II Study – TCTMD
New Drug Helps Tame Uncontrolled High Blood Pressure – HealthDay
SR | Biomarkers as point‐of‐care tests to guide use of antibiotics in people with acute respiratory infections in primary care.
11 Nov, 2022 | 13:47h | UTC
M-A | Cardiovascular safety of febuxostat and allopurinol in patients with gout.
11 Nov, 2022 | 13:41h | UTC
M-A | Head-to-head trials comparing sulfonylureas and low hypoglycemic risk antidiabetic drugs.
11 Nov, 2022 | 13:38h | UTC
M-A | Medication reviews and deprescribing as a single intervention in falls prevention.
11 Nov, 2022 | 12:53h | UTC
NICE Guideline Update | Colonoscopic surveillance in adults with inflammatory bowel disease or adenomas.
10 Nov, 2022 | 14:16h | UTCRelated:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
RCT | Intermediate-dose no better than low-dose LMWH in pregnant and post-partum women with previous thromboembolism.
10 Nov, 2022 | 14:12h | UTCIntermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial – The Lancet (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Intermediate-dose versus low-dose low-molecular-weight heparin in pregnant and post-partum women with a history of venous thromboembolism (Highlow study): an open-label, multicentre, randomised, controlled trial https://t.co/9zHeUIda7o
— Saskia Middeldorp (@MiddeldorpS) October 28, 2022
Study | In hypertensive disorders of pregnancy, the levels of angiogenic factors may stratify the risk of severe preeclampsia.
10 Nov, 2022 | 14:11h | UTCCirculating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy – NEJM Evidence
Commentary on Twitter
This study measured the ratio of serum soluble fms-like tyrosine kinase (sFlt-1) to placental growth factor (PIGF) in pregnant pts hospitalized with HTN. An sFLT-1:PIGF ratio ≥ 40 stratified the risk of progressing to severe pre-eclampsia within 2 wks. https://t.co/H0uSHT2bN7 pic.twitter.com/ZKRvHsqLA4
— NEJM Evidence (@NEJMEvidence) November 9, 2022
RCT | Mindfulness-based stress reduction vs. escitalopram for the treatment of adults with anxiety disorders.
10 Nov, 2022 | 14:09h | UTCMindfulness-Based Stress Reduction vs Escitalopram for the Treatment of Adults With Anxiety Disorders: A Randomized Clinical Trial – JAMA Psychiatry (free for a limited period)
Commentaries:
Mindfulness worked as well for anxiety as drug in study – Associated Press
Meditation works as well as a popular drug to reduce anxiety, study finds – NPR
Commentary on Twitter
This randomized, controlled #anxiety disorder treatment trial comparing a standardized, evidence-based mindfulness-based intervention with pharmacotherapy and found that mindfulness based stress reduction was non-inferior to escitalopram https://t.co/P7KJQlT03g
— JAMA Psychiatry (@JAMAPsych) November 9, 2022
Cohort Study | Study shows subclinical Hyperthyroidism is linked to an increased risk of fractures.
10 Nov, 2022 | 14:08h | UTCAssociation Between Subclinical Thyroid Dysfunction and Fracture Risk – JAMA Network Open
Commentary: Does Subclinical Hyperthyroidism Raise Fracture Risk? – Medscape (free registration required)
Commentary on Twitter
Subclinical hyperthyroidism may be an independent risk factor associated with fracture, highlighting a potential role for more aggressive screening and monitoring to prevent bone mineral disease. #OAReasearch https://t.co/LQVjaNU1zM
— JAMA Network Open (@JAMANetworkOpen) November 8, 2022
Review | New horizons in the ageing autonomic nervous system: orthostatic hypotension and supine hypertension.
10 Nov, 2022 | 13:37h | UTC
Retrospective Cohort Study | Trends, predictors, and outcomes of CV complications at delivery associated with gestational diabetes.
10 Nov, 2022 | 13:34h | UTC
Commentary on Twitter
https://twitter.com/ErinMichos/status/1586008508331266048
Guidelines | Managing functional dyspepsia overlapping with other gastrointestinal symptoms.
9 Nov, 2022 | 12:26h | UTC
Cohort Study | Association of hormone therapy with depression during menopause.
9 Nov, 2022 | 12:17h | UTCCommentaries:
Expert reaction to study looking at HRT and depression during the menopause – Science Media Centre
Commentary on Twitter
Systemic hormone therapy (HT) before and during menopause is associated with higher risk of depression, especially in the years immediately after initiation; locally administered HT is associated with lower risk of depression for women ≥54 years. https://t.co/8k44K8SVtp
— JAMA Network Open (@JAMANetworkOpen) November 1, 2022
Canadian guideline for the prevention and management of cardiovascular disease in primary care.
8 Nov, 2022 | 12:37h | UTCNews Release: New one-stop guideline for cardiovascular health in Canada – Canadian Medical Association Journal
NICE Guideline | Obesity: identification, assessment and management.
8 Nov, 2022 | 12:35h | UTCRelated:
ASMBS Guidelines | Indications for metabolic and bariatric surgery.
AGA clinical practice guideline on pharmacological interventions for adults with obesity.
Guideline | Preventing obesity in midlife women.
Review | Management of heart failure with reduced ejection fraction.
8 Nov, 2022 | 12:17h | UTCManagement of heart failure with reduced ejection fraction – Heart
Review | Oral anticoagulant use in patients with atrial fibrillation and chronic kidney disease.
8 Nov, 2022 | 12:02h | UTC
Cohort Study | Menstrual cycle regularity and length across the reproductive lifespan and risk of cardiovascular disease.
8 Nov, 2022 | 11:54h | UTCCommentary: Irregular, Long Menstrual Cycles Up Risk for Cardiovascular Disease – HealthDay
Commentary on Twitter
Irregular and long menstrual cycles across a woman’s reproductive lifespan may identify women with a higher risk of cardiovascular disease, even after accounting for established CVD risk factors. #OAResearch #OAWeek https://t.co/BxNveNAqg5
— JAMA Network Open (@JAMANetworkOpen) October 29, 2022
CDC Clinical Practice Guideline for prescribing opioids for pain.
7 Nov, 2022 | 13:00h | UTCCommentaries:
CDC issues new opioid prescribing guidance, giving doctors more leeway to treat pain – NPR
NICE Guideline | Self-harm: assessment, management and preventing recurrence.
7 Nov, 2022 | 12:58h | UTC
RCT | In patients with CKD (eGFR 20-45 mL/min per 1.73 m2), Empagliflozin reduced the risk of progression of kidney disease.
7 Nov, 2022 | 12:56h | UTCEmpagliflozin in Patients with Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: EMPA-KIDNEY supports SGLT2 inhibition for chronic kidney disease – medwire News
Video Summary: EMPA-KIDNEY results: Empagliflozin reduces kidney disease progression and cardiovascular deaths
Commentary on Twitter
In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx pic.twitter.com/EPU6Rl14F1
— NEJM (@NEJM) November 4, 2022
RCT | Triglyceride lowering with Pemafibrate fails to reduce CVD risk in patients with Type 2 DM and hypertriglyceridemia.
7 Nov, 2022 | 12:54h | UTCTriglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk – New England Journal of Medicine (link to abstract – $ for full-text)
News Releases:
Commentaries:
Pemafibrate Fails to Lower CVD Risk in Patients With High Triglycerides: PROMINENT – TCTMD
Commentary on Twitter
In a randomized trial, the incidence of cardiovascular events was not lower in patients with diabetes, HTG, and low HDL cholesterol levels who received pemafibrate, although TG, VLDL cholesterol, remnant cholesterol, and Apo C-III levels decreased. #AHA22 https://t.co/bNtIAwWTX0 pic.twitter.com/yWaTWarlsv
— NEJM (@NEJM) November 5, 2022